Acupath Laboratories Inc. Releases Results of White Paper Highlighting Clinical Utility of the Acu-URO17 Bladder Cancer Biomarker

PLAINVIEW, N.Y., Sept. 5, 2023 /PRNewswire/ -- Acupath Labs released a white paper highlighting the impressive results of a large-scale internal study analyzing the clinical utility of its Acu-UR017 bladder cancer biomarker. Acu-URO17 is a non-invasive, cost-effective urine-based biomarker used in the diagnosis and management of bladder cancer, the 6^th most common form of cancer in the US. Commercially launched nationwide in 2019, Acupath has performed over 25,000 tests and has helped urology practices nationwide leverage the inherent and significant clinical and financial benefits of the assay.

Primary positioned as a "rule out" tool, Acu-URO17 had a negative predictive value (NPV) of 99.9%, thus helping to offset the problematic low sensitivity of traditional urine cytology, while at the same time serving as a valuable risk-stratification tool on atypical urine cytology diagnoses. Further, Acu-URO17 had a sensitivity of 96% and specificity of 82% on urine cytology cases that yielded high-grade urothelial cancer diagnoses. These results are consistent with the three peer-reviewed studies that have previously been published.

"Our team has worked tirelessly over the last 4+ years to optimize this assay and make it available to clients nationwide, and these results support the significant value that Acu-URO17 provides for both clinicians and patients. We will continue working with our clients and industry partners to increase the adoption of Acu-URO17 and provide support and guidance to urology practices and labs that seek to incorporate Acu-URO17 into their existing operations.", says John Cucci, Chief Sales Officer of Acupath.

"I have seen firsthand the clinical utility provided by Acu-URO17, especially when performed in conjunction with both traditional urine cytology and FISH. This innovative biomarker has consistently demonstrated its ability to help clinicians triage patients at risk of bladder cancer and provide the best possible diagnostic and treatment plan.", says Michael Matthews, Director of Molecular Diagnostics at Acupath.

For a PDF of the white paper and / or information on how to order Acu-URO17 or incorporate into your lab, email [email protected].

About Acupath Laboratories, Inc.
Founded in 1998 and based in Plainview, New York, Acupath is a provider of sub-specialized anatomic pathology services focused on the following specialties; Urology, Gastroenterology, Dermatology, Women's Health, Otolaryngology, Podiatry, and Hematology / Oncology. Acupath offers an extensive test menu on both a global and TC/PC basis, processes over 500,000 specimens annually, and is the first lab worldwide to offer URO17™, an innovative bladder cancer biomarker, designated as a "Breakthrough Device" by the FDA in 2019.

Contact:
Public Relations
Acupath Laboratories, Inc
516-775-8103
[email protected] 

SOURCE ACUPATH LABORATORIES, INC.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED